SCD-044 Tablets 0.6mg
Sponsors
Sun Pharmaceutical Industries Limited
Conditions
atopic dermatitismoderate to severe plaque psoriasis
Phase 2
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Plaque Psoriasis
CompletedCTIS2023-506477-35-00
Start: 2024-04-02End: 2025-08-27Target: 63Updated: 2024-10-23
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF SCD-044 IN THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS
CompletedCTIS2024-511615-16-00
Start: 2023-08-25End: 2024-11-25Target: 43Updated: 2024-10-24